32Durvalumab or Pembrolizumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin Alone as First-Line Therapy for Advanced Cholangiocarcinoma: A Meta-Analysis
The Oncologist · 01.06.2026 · 31 (Supplement_1)
DOI: 10.1093/oncolo/oyag205.033 ↗Kurz gefasst
Metaanalyse in der Zeitschrift The Oncologist, online erschienen am 23.06.2026. Verfasst von Abdullah Esmail und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Cholangiocarcinoma (CCA) is a rare, aggressive malignancy of the bile duct epithelium with rising incidence and mortality. Curative surgery is feasible in few cases; for unresectable or metastatic disease, systemic therapy is standard. Gemcitabine plus cisplatin (GemCis) has been the first-line backbone, but phase 3 trials (TOPAZ-1 and KEYNOTE-966) demonstrated overall survival (OS) benefit with added immune checkpoint inhibitors (durvalumab or pembrolizumab). This systematic review and meta-analysis evaluates the efficacy and safety of immunotherapy (10) plus GemCis versus GemCis alone in advanced CCA.
Methods
We systematically searched PubMed, Embase, Scopus, and Google Scholar for English-language studies (2009-2025) including randomized controlled trials (RCTs) and cohort studies of first-line GemCis alone or with durvalumab or pembrolizumab in unresectable/metastatic CCA. Primary endpoint: OS. Secondary: progression-free survival {PFS) and grade 3-4 adverse events (AEs) per CTCAE. Kaplan-Meier curves were digitized, and individual patient data reconstructed using IPD tools for pooled estimates. Random-effects models generated hazard ratios (HRs) and pooled medians; heterogeneity assessed via I2 Results We included 3,703 patients from TOPAZ-1, KEYNOTE-966, ABC-01/02, and six cohort studies: 1,737 on GemCis alone, 1,433 on GemCis + durvalumab, and 533 on GemCis + pembrolizumab. In the full meta-analysis, GemCis + durvalumab showed the best outcomes (median OS 14.1 months, PFS 7.38 months) versus GemCis + pembrolizumab (OS 12.8 months, PFS 6.62 months) and GemCis alone (OS 9.27 months, PFS 5.81 months). Restricting to RCTs only, 10 + GemCis improved OS versus GemCis alone (median 12.82 vs. 11.1 months; HR 0.78, 95% Cl 0.71-0.86, p < 0.001), with no significant PFS difference (p = 0.20). Grade 3-4 AEs were infrequent across arms; thrombocytopenia was higher with pembrolizumab (p = 0.0002), but other severe toxicities were comparable.
Conclusions
Adding immunotherapy to GemCis significantly enhances survival in unresectable/metastatic CCA, with durvalumab + GemCis providing the most pronounced benefit in this pooled analysis incorporating RCTs and real-world cohorts. Regimens were well-tolerated with manageable toxicity. These findings reinforce chemoimmunotherapy as first-line standard and highlight potential differential efficacy between PD-Ll and PD 1 inhibitors warranting further study.
Zitieren
APA
Esmail, A., Abdelrahim, S., Hamadneh, Y., Mustafa, N., Al-Najjar, E., & Abdelrahim, M. (2026). 32Durvalumab or Pembrolizumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin Alone as First-Line Therapy for Advanced Cholangiocarcinoma: A Meta-Analysis. The Oncologist, 31(Supplement_1). https://doi.org/10.1093/oncolo/oyag205.033
Vancouver
Esmail A, Abdelrahim S, Hamadneh Y, Mustafa N, Al-Najjar E, Abdelrahim M. 32Durvalumab or Pembrolizumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin Alone as First-Line Therapy for Advanced Cholangiocarcinoma: A Meta-Analysis. The Oncologist. 2026;31(Supplement_1). doi:10.1093/oncolo/oyag205.033
BibTeX
@article{Esmail2026,
author = {Esmail, Abdullah and Abdelrahim, Saifudeen and Hamadneh, Yazan and Mustafa, Naur and Al-Najjar, Ebtesam and Abdelrahim, Maen},
title = {32Durvalumab or Pembrolizumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin Alone as First-Line Therapy for Advanced Cholangiocarcinoma: A Meta-Analysis},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {Supplement_1},
doi = {10.1093/oncolo/oyag205.033}
}
EUVIMED